2 Jul 2015 07:16
2 JulyΒ 2015
Β
PhormΒ CorporationΒ Limited
("Phorm"Β orΒ theΒ "Company")
DirectorateΒ Change
Phorm (AIM: PHRM), a leading internet personalisation technology company, is pleased to announce the appointment of Mr Michael Alkin as a Non-Executive Director of the Company with immediate effect.
Mr Alkin is currently a Portfolio Manager of the Tullamore Fund at Hilton Capital Management, LLC. Prior to joining Hilton Capital, Mr Alkin worked for 17 years in the hedge fund industry, most recently as a Portfolio Manager at Kellner Capital, having previously spent 7 years at Knott Partners LP as a Senior Partner of its US$1.5 billion equity hedge fund. Prior Analyst and Portfolio Manager positions include Walker Smith Capital, Blackbird Capital Partners (of which he was co-founder), Gilder Gagnon Howe, RH Capital, Scout Capital, Zweig Dimenna and Windsor Partners. Mr Alkin is a graduate of Dowling College, Long Island, holding a B.B.A. in Accounting.
Β
KentΒ Ertugrul, Chairman andΒ CEOΒ ofΒ Phorm,Β commented:
"We are delighted to welcome Michael to the Phorm Board. His valuable experience of international capital markets and analytical skillset will assist us with the group's future growth and development."
Β
AdditionalΒ informationΒ on Mr Michael Alkin
TheΒ following additionalΒ information is providedΒ inΒ accordance withΒ paragraphΒ (g)Β ofΒ Schedule TwoΒ toΒ theΒ AIMΒ RulesΒ forΒ Companies:
Β
Michael Craig AlkinΒ (aged 50)
Β
Current Directorships/Partnerships Β | Past Directorships/Partnerships (last 5 years) |
Reverend Nat's Hard Cider LLC | None |
Mr Alkin is currently interested in 7,555,813 ordinary shares of nil par value each in the capital of Phorm, representing approximately 0.90 per cent. of the Company's existing issued share capital.
There is no other information that is required to be disclosed pursuant to paragraph (g) of Schedule Two to the AIM Rules for Companies.
Β
Β
-Ends-
ForΒ furtherΒ informationΒ pleaseΒ contact:Β PhormΒ CorporationΒ Limited
AndyΒ CroxsonΒ (analystsΒ andΒ investors) +44Β (0)Β 203Β 397Β 6001
Β
UKΒ Investors
MirabaudΒ SecuritiesΒ LLPΒ (Broker) +44Β 20Β 7321Β 2508
JasonΒ WoollardΒ PeterΒ Krens
Β
StrandΒ HansonΒ LimitedΒ (NominatedΒ Adviser) +44Β 20Β 7409Β 3494
JamesΒ HarrisΒ MatthewΒ ChandlerΒ JamesΒ Dance
Β
USΒ Investors
Lippert/HeilshornΒ and AssociatesΒ (InvestorΒ Relations) +1Β 212Β 838Β 3777
JohnΒ Heilshorn
Β
AboutΒ Phorm
PhormΒ isΒ aΒ globalΒ personalisationΒ technologyΒ companyΒ thatΒ makesΒ contentΒ andΒ advertisingΒ moreΒ relevantΒ toΒ theΒ consumer.Β Phorm'sΒ innovativeΒ platformΒ preservesΒ userΒ privacyΒ andΒ deliversΒ aΒ moreΒ interestingΒ onlineΒ experience.
Β
Phorm'sΒ industryΒ leadingΒ technologyΒ enablesΒ itsΒ InternetΒ ServiceΒ ProviderΒ ("ISP")Β partnersΒ toΒ offerΒ aΒ newΒ typeΒ ofΒ onlineΒ advertisingΒ platformΒ andΒ aΒ freeΒ consumerΒ internetΒ contentΒ feature,Β ensuringΒ moreΒ relevantΒ advertisementsΒ andΒ personalised content forΒ opted-inΒ users.
Β
Phorm'sΒ advertisingΒ platformΒ revolutionisesΒ currentΒ standardsΒ ofΒ onlineΒ privacy,Β fullyΒ protectingΒ theΒ identityΒ ofΒ consumers.Β Phorm'sΒ solutionΒ isΒ completelyΒ opt-in.Β OnlyΒ thoseΒ usersΒ consentingΒ toΒ theΒ serviceΒ areΒ profiledΒ andΒ onlyΒ ever onΒ anΒ anonymousΒ basis.
Β
Phorm's partnersΒ includeΒ leading ISPs,Β Publishers, Advertising NetworksΒ and Advertisers.
Β
Phorm,Β underΒ aΒ predecessorΒ holding company,Β was admitted to theΒ AIMΒ marketΒ of the London StockΒ ExchangeΒ inΒ 2004.
Β
ForΒ moreΒ information, pleaseΒ visit:Β www.phorm.com
Follow the stocks